{"id":488,"date":"2019-01-01T10:26:59","date_gmt":"2019-01-01T10:26:59","guid":{"rendered":"http:\/\/clinicalbiochemistry.net\/?page_id=488"},"modified":"2019-01-01T10:39:57","modified_gmt":"2019-01-01T10:39:57","slug":"book-chapter-biophysical-and-molecular-targets","status":"publish","type":"page","link":"http:\/\/clinicalbiochemistry.net\/?page_id=488","title":{"rendered":"Book Chapter: Biophysical and molecular targets."},"content":{"rendered":"\n

Slevin, M., Carroll, M., Murgatroyd, C. & McDowell, G.<\/strong>(2014) \u2018Biophysical and molecular targets.\u2019 In: Kibos, A.S., Knight, B.P., Essebag, V., Fishberger, S.B., Slevin, M. & Tintoiu I. (eds.) (2014) Cardiac Arrhythmias: From Basic Mechanisms to State-of-the-art Management<\/em>. London: Springer pp. 335-343 (9 pages)<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Cardiac arrhythmias represent a large heterogeneous collection of heart abnormalities characterized by the presence of electrical dysfunction caused by abnormalities in the conduction of nerve signals. In these cases, the heart either beats irregularly, too fast or too slowly. Arrhythmia of the heart can have both acute and chronic long-term life threatening effects including cardiac arrest, stroke, embolism and increased propensity for development of atherosclerosis and unstable plaques susceptible to thrombosis. Whilst historical facts types of arrhythmia and epidemiology of this group of diseases has been covered in detail by other authors, it is worth reiterating the importance of identifying and treating this complex group of disorders that can account for a large proportion of both asymptomatic and symptomatic disease following acute myocardial infarction (46%)1<\/sup>, with high-degree atrioventricular block associated with a very high degree of cardiac death. Whilst currently available implantable cardioverter defibrillator therapy is now considered to be the most effective against malignant arrhythmias, these are in fact only effective at treating some kinds of arrhythmia and are extremely expensive making the search for more effective and specific pharmaceuticals imperative. <\/p>\n\n\nLink to Publisher<\/span><\/a>","protected":false},"excerpt":{"rendered":"

Slevin, M., Carroll, M., Murgatroyd, C. & McDowell, G.(2014) \u2018Biophysical and molecular targets.\u2019 In: Kibos, A.S., Knight, B.P., Essebag, V., Fishberger, S.B., Slevin, M. & Tintoiu I. (eds.) (2014) Cardiac Arrhythmias: From Basic Mechanisms to State-of-the-art Management. London: Springer pp. 335-343 (9<\/p>\n","protected":false},"author":1,"featured_media":486,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"_links_to":"","_links_to_target":""},"jetpack_shortlink":"https:\/\/wp.me\/P9tPlw-7S","jetpack-related-posts":[{"id":121,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=121","url_meta":{"origin":488,"position":0},"title":"Research Papers","date":"December 22, 2017","format":false,"excerpt":"Body, R., McDowell, G., Carley, S., Ferguson, J. & Mackway-Jones, K. (2010) \u2018Diagnosing acute myocardial infarction with troponins: how low can you go?\u2019 Emerg Med J. 27 pp. 292-296. Body, R., Carley, S., Wibberley, C., McDowell, G., Ferguson, J. & Mackway- Jones, K. (2010) \u2018The value of symptoms and signs\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":968,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=968","url_meta":{"origin":488,"position":1},"title":"Self-Funded PhD Opportunity: Cardiovascular Disease in ESRD","date":"August 24, 2022","format":false,"excerpt":"A Multi-Omics approach to understanding cardiovascular risk in patients with End-Stage Kidney Disease. End-stage Kidney failure, also known as End-stage Kidney Disease (ESKD), is the final, irreversible stage of chronic kidney disease, where kidney function has worsened to the point that the kidneys can no longer function independently.\u00a0Cardiovascular complications rather\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2019\/02\/iStock_17432100_MEDIUM.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":499,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=499","url_meta":{"origin":488,"position":2},"title":"Acetlycholine & Monomeric C-Reactive Protein","date":"January 1, 2019","format":false,"excerpt":"Slevin, M., Lemma, R.S., Zeinolabediny, Y., Liu, D., Ferris, G.R., Caprio, V., Phillips, N., Di Napoli, M., Guo, B., Zeng, X., AlBaradie, R., Binsaleh, N.K.,\u00a0McDowell, G. & Fang, W-H. (2018) Acetylcholine inhibits monomeric C-Reactive Protein inducd inflammation, endothelial cell adhesion and platelet aggregation; A potential therapeutic. Frontiers in Immunology 9\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2017\/12\/Lab-Equipment-Pages.png?fit=800%2C534&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":659,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=659","url_meta":{"origin":488,"position":3},"title":"MACS Rule","date":"February 7, 2019","format":false,"excerpt":"Body, R., Carley, S.,\u00a0McDowell, G., Pemberton, P., Burrows, G., Cook, G., Lewis, P.S., Smith, A., Mackway-Jones, K. (2014) \u2018The Manchester Acute Coronary Syndromes (MACS) decision rule for suspected cardiac chest pain: derivation and external validation.\u2019 Heart 100 pp. 1462-1468.\u00a0 Objective:We aimed to derive and validate a clinical decision rule (CDR)\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2019\/01\/MACS-Paper-e1549807711724.png?fit=400%2C331&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":49,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=49","url_meta":{"origin":488,"position":4},"title":"Research Expertise","date":"December 17, 2017","format":false,"excerpt":"\u00a0 Research Expertise Cardiology Cardiovascular Disease Acute Cardiology Acute Coronary Syndromes Diagnostics Heart Failure Diagnostics Heart Failure Physiology and Patho-physiology Angiogenesis Cardiac Biomarkers Diagnostic and Prognostic role of Cardiac Biomarkers Methodological Knowledge Immunoassay Point of Care Testing (Near Patient Testing) Cell Biology Clinical Trials Diagnostic Studies Cohort Studies Biomarker development\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":629,"url":"http:\/\/clinicalbiochemistry.net\/?page_id=629","url_meta":{"origin":488,"position":5},"title":"Risk Factors and AMI","date":"February 7, 2019","format":false,"excerpt":"Body, R.,\u00a0McDowell, G.,Carley, S. & Mackway-Jones, K. (2008) \u2018Do risk factors for chronic coronary heart disease help diagnose acute myocardial infarction in the emergency department.\u2019\u00a0Resuscitation79 pp. 41-45.\u00a0 Background:Hypertension, hyperlipidaemia, diabetes mellitus, tobacco smoking and a family history of premature coronary artery disease are known to be risk factors for the\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/clinicalbiochemistry.net\/wp-content\/uploads\/2019\/01\/Risk-factors-for-ED-diagnosis-e1549807935709.png?fit=400%2C313&resize=350%2C200","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/488"}],"collection":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=488"}],"version-history":[{"count":2,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/488\/revisions"}],"predecessor-version":[{"id":494,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/pages\/488\/revisions\/494"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=\/wp\/v2\/media\/486"}],"wp:attachment":[{"href":"http:\/\/clinicalbiochemistry.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}